SELLAS Life Sciences To Present SLS009 Phase 1 Data From Acute Myeloid Leukemia Patients At The 2024 European School Of Haematology Conference
SELLAS Life Sciences To Present SLS009 Phase 1 Data From Acute Myeloid Leukemia Patients At The 2024 European School Of Haematology Conference
SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that data from the acute myeloid leukemia cohort of patients in the Phase 1 dose-escalation study of SLS009 (formerly GFH009) will be presented in an oral presentation at the 2024 European School of Haematology Acute Leukaemias (ESH) Conference: 4th How to Diagnose and Treat Acute Leukaemias, taking place March 1-3, 2024, in Stockholm, Sweden.
专注于为各种癌症适应症开发新疗法的后期临床生物制药公司SELLAS Life Sciences Group, Inc.（纳斯达克股票代码：SLS）（“SELLAS” 或 “公司”）今天宣布，SLS009（前身为 GFH009）1期剂量递增研究中急性髓系白血病患者群体的数据将在2024年欧洲学院的口头陈述中公布血液学急性白血病（ESH）会议：第四届如何诊断和治疗急性白血病，将于2024年3月1日至3日在瑞典斯德哥尔摩举行。
The presentation details are below:
演示详情如下：
Title: Phase 1 Dose-Escalation Study of GFH009 in Acute Myeloid Leukemia
Session Date and Time: Sunday, March 3, 2024, at 12 pm CET
Session Title: Leukemia Treatment Challenges
Presenter: Dr. Tapan Kadia, Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston, Texas
Abstract Number: 6192705
标题：GFH009 治疗急性髓系白血病的 1 期剂量递增研究
会议日期和时间：欧洲中部时间 2024 年 3 月 3 日星期日中午 12 点
会议标题：白血病治疗的挑战
主持人：塔潘·卡迪亚博士，德克萨斯大学白血病系教授，德克萨斯州休斯敦医学博士安德森癌症中心
摘要编号：6192705